生产企业：Insmed Incorporated
Brensocatib (BRINSUPRI) is a small molecule, oral, once-daily, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), approved for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. It is approved in the U.S., Europe, and Japan, with the MHLW approval based on results from the Phase 3 ASPEN study.
Brensocatib (BRINSUPRI) is a small molecule, oral, once-daily, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), approved for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. It is approved in the U.S., Europe, and Japan, with the MHLW approval based on results from the Phase 3 ASPEN study.
Brensocatib是一种口服、每日一次的小分子可逆性二肽基肽酶1（DPP1）抑制剂，通过抑制中性粒细胞中中性粒细胞丝氨酸蛋白酶（NSPs）的活化，靶向NCFB慢性气道炎症的关键驱动因素。
用于非囊性纤维化支气管扩张症（NCFB）成人和12岁及以上儿科患者的治疗。
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
